Neurocrine biosciences presented cahtalyst™ pediatric study baseline characteristics and cahtalog™ registry data at pes 2024

Cahtalyst™ pediatric study baseline characteristics data highlight need for novel treatments in children and adolescents with congenital adrenal hyperplasia (cah) cahtalog™ registry data of glucocorticoid treatment patterns in pediatric and adult patients illustrates the challenges of long-term cah management san diego , may 3, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today presented the cahtalyst™ pediatric phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency enrolled in the study, along with cahtalog™ registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with cah. these data demonstrate the limitations of current cah treatment approaches in pediatric patients, comorbidities associated with the condition and/or current treatment, including obesity, advanced bone age, and early puberty, and the difficulty in managing the disease effectively as cah patients age into adults.
NBIX Ratings Summary
NBIX Quant Ranking